NASDAQ:TRVN Trevena (TRVN) Stock Price, News & Analysis $0.23 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.22▼$0.2350-Day Range$0.21▼$0.4252-Week Range$0.19▼$1.12Volume102,736 shsAverage Volume517,860 shsMarket Capitalization$4.15 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Trevena alerts: Email Address Trevena MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,111.4% Upside$5.00 Price TargetShort InterestHealthy0.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.22Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.29) to ($0.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.43 out of 5 stars 3.5 Analyst's Opinion Consensus RatingTrevena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTrevena has only been the subject of 1 research reports in the past 90 days.Read more about Trevena's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.30% of the float of Trevena has been sold short.Short Interest Ratio / Days to CoverTrevena has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Trevena has recently decreased by 72.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTrevena does not currently pay a dividend.Dividend GrowthTrevena does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRVN. Previous Next 2.1 News and Social Media Coverage News SentimentTrevena has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Trevena this week, compared to 1 article on an average week.Search Interest9 people have searched for TRVN on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat Follows5 people have added Trevena to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevena insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Trevena is held by insiders.Percentage Held by InstitutionsOnly 13.56% of the stock of Trevena is held by institutions.Read more about Trevena's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Trevena are expected to grow in the coming year, from ($1.29) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevena is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevena is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Trevena's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.Click here to learn more. About Trevena Stock (NASDAQ:TRVN)Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.Read More TRVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRVN Stock News HeadlinesJuly 25 at 9:23 PM | msn.comAttorney John Trevena speaks after hit-and-run crash left him seriously hurt: 'We were going back and forth'July 24 at 12:48 AM | yahoo.comAttorney John Trevena injured in hit-and-run crash in Pinellas CountyJuly 26, 2024 | Porter & Company (Ad)I’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.July 20, 2024 | americanbankingnews.comTrevena (NASDAQ:TRVN) Receives New Coverage from Analysts at StockNews.comJuly 8, 2024 | globenewswire.comTrevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty FinancingJune 20, 2024 | globenewswire.comTrevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy ModelsMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Trevena Amid Strategic Focus on Promising Drug TRV045May 16, 2024 | msn.comTrevena Reports Progress in Pain and Epilepsy Treatment Development, Amid Financial AdjustmentsJuly 26, 2024 | Porter & Company (Ad)I’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documentary I will provide you with all the details of this one-of-a-kind investment.May 15, 2024 | investorplace.comTRVN Stock Earnings: Trevena Beats EPS for Q1 2024May 15, 2024 | globenewswire.comTrevena Reports First Quarter 2024 Results and Provides Business UpdateApril 28, 2024 | finance.yahoo.comTrevena, Inc. (TRVN)April 28, 2024 | benzinga.comTrevena Stock (NASDAQ:TRVN), Analyst Ratings, Price Targets, PredictionsApril 21, 2024 | msn.comTrevena Cross free art exhibition featuring local artistsApril 18, 2024 | msn.comTrevena (TRVN) Price Target Decreased by 7.69% to 6.12April 5, 2024 | morningstar.comTrevena Inc TRVNApril 4, 2024 | msn.comDanny Huston, Graham Greene, Martin Sensmeier, Oliver Trevena & Devaughn Nixon Join Joel Kinnaman Thriller ‘Ice Fall', Filming Underway In BulgariaApril 3, 2024 | msn.comTrevena Ramps Up Efforts on TRV045, Turns Attention Away from OLINVYK Amid Challenging Hospital EnvironmentSee More Headlines Receive TRVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRVN CUSIPN/A CIK1429560 Webwww.trevena.com Phone(610) 354-8840FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+2,166.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,290,000.00 Net MarginsN/A Pretax Margin-1,278.60% Return on Equity-1,018.15% Return on Assets-103.12% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual Sales$3.12 million Price / Sales1.30 Cash FlowN/A Price / Cash FlowN/A Book Value($0.44) per share Price / Book-0.50Miscellaneous Outstanding Shares18,340,000Free Float17,901,000Market Cap$4.05 million OptionableOptionable Beta1.05 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Carrie L. Bourdow (Age 61)President, CEO & Chairman Comp: $1MMr. Barry Shin (Age 52)Executive VP, COO & CFO Comp: $670.02kDr. Mark A. Demitrack M.D. (Age 66)Senior VP & Chief Medical Officer Comp: $690.32kDr. Howard A. Rockman M.D.Scientific Founder, Consultant and Member of Scientific Advisory BoardMr. Joel SolomonVP, General Counsel & Chief Compliance OfficerMr. Michael CatalanoVice President of MarketingMr. Robert T. Yoder (Age 58)Senior VP, Chief Business Officer & Head of Commercial Operations Comp: $490.64kMs. Patricia M. Drake (Age 58)Senior VP & Chief Commercial Officer More ExecutivesKey CompetitorsAptorum GroupNASDAQ:APMVBI VaccinesNASDAQ:VBIVSensei BiotherapeuticsNASDAQ:SNSEAytu BioPharmaNASDAQ:AYTUCan-Fite BioPharmaNYSE:CANFView All Competitors TRVN Stock Analysis - Frequently Asked Questions How have TRVN shares performed this year? Trevena's stock was trading at $0.7221 at the start of the year. Since then, TRVN stock has decreased by 68.7% and is now trading at $0.2261. View the best growth stocks for 2024 here. How were Trevena's earnings last quarter? Trevena, Inc. (NASDAQ:TRVN) announced its quarterly earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter. When did Trevena's stock split? Trevena shares reverse split on Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Trevena? Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Trevena own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB) and Zosano Pharma (ZSAN). This page (NASDAQ:TRVN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
